Arcus Biosciences RCUS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128M-20.8% | -$106M+21.5% | -$135M— | $0+100% | -$112M-19.1% | ||
| $2M-33.3% | $3M+50.0% | $2M0.0% | $2M-33.3% | $3M0.0% | ||
| $19M+26.7% | $15M+7.1% | $14M-6.7% | $15M-6.3% | $16M-5.9% | ||
| -$138M-15.0% | -$120M-23.7% | -$97M+27.1% | -$133M-0.8% | -$132M-32.0% | ||
| $0-100% | $1M— | —— | —— | $1M0.0% | ||
| $114M— | —— | $79M-42.3% | $137M+328% | $32M— | ||
| $3M-99.0% | $286M+3,475% | $8M-84.6% | $52M-63.4% | $142M— | ||
| -$21M— | —— | —— | $56M+33.3% | $42M— | ||
| -$138M-14.0% | -$121M-24.7% | -$97M+27.1% | -$133M0.0% | -$133M-31.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Arcus Biosciences's cash flow data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.